Risk Tweets by @chemobrainfog

The Wrong Approach to Breast Cancer

The Wrong Approach to Breast Cancer

Thought provoking, well written by @peggyorenstein My only Q, Not sure if risk to reduce mets significant #bcsm

“RT @margaretaindc (@fastercures): Bringing patient perspective into how we think of risk-benefit is critical-Commissioner Hamburg #PhRMA14”

“Seems promising? RT @rsm2800: Coleman BIS meta: Breast ca mortality postmenop = 17% reduction in risk of death (3.1% absolute gain) #SABCS13”

“RT @jrgralow: Chemoprevention not appropriate 4 gen'l population. Option 4 some at hi risk-risks/benefits need 2B carefully weighed #sabcs13”

“RT @rsm2800: Clarify, I think risk-reducing Rx w/tam, raloxifene, maybe AI UNDERUTILIZED 4 hi-risk pts (prevent, not Rx of disease) #SABCS13”

“Come ON. Here we go w/headlines RT @ap New option 2 prevent breast cancer: Hormone-blocker Arimidex cuts risk in half ”

“I would be first in line 4 trial 2 develop solid evidence re-use of bisphos to reduce risk of mets. Risk info may matter less to me #SABCS13”

“Important info, now risk v reward? RT @teamoncology: There are preclinical antitumor activity for both bisphosphanate/denosumab. #SABCS13”

“All should pay attention! RT @EBantug: Up now at #SABCS13 -MRI screening in avg risk women #bcsm”

Risks: MT @JNCI_Now Adding trastuzumab 2 anthracycline-based therapy in adjuvant disease increases cardiac toxicity btn 3-5fold. #SABCS13”

“RT @carradaza: FDA making changes so clinical review process takes benefit-risk framework into account. #P4C2013”

“RT @LillyPad: .@US_FDA at 1st step in integration of benefit/risk framework into drug review. Will be a several month effort. #P4C2013”

Twitter / chemobrainfog: FDA recalibrating benefit risk ...

Twitter / chemobrainfog: FDA recalibrating benefit risk ...

FDA recalibrating benefit risk equation #P4C2013

Twitter / chemobrainfog: Panel abt risk benefit and ...

Twitter / chemobrainfog: Panel abt risk benefit and ...

Panel abt risk benefit and FDA position. #P4C2013

Twitter / chemobrainfog: FDA recalibrating benefit risk ...

Twitter / chemobrainfog: FDA recalibrating benefit risk ...

FDA recalibrating benefit risk equation

“Waiting for discussion of risk-benefit equation. Shouldn't patient drive acceptable risk? I say yes but evidence matters! #P4C2013”

“The common fund for "high risk" projects being discussed by @NIHDirector - AGREE-need to change paradigm! #P4C2013”

“Takeaway: timeliness, tapping into brightest brains, willing to TAKE RISK and work through toxicology issues in new drug develop. #P4C2013”

“A1 All you need to be at risk for lung cancer is to have lungs. And breathe. Stop the Blame Game. It's counterproductive. #lcsm”

“RT @BarbBristow Yes, @DrSusanLove Docs not explaining that big risk is mets not 2nd cancer #actwlove #bcsm #abcdrbchat”

AnneMarie Ciccarella Twitter

See what's Trending Now for @chemobrainfog

See All Trending »
x
AnneMarie Ciccarella

Follow @chemobrainfog on Twitter